RecruitingPhase 2

Precision Biomarkers to Detect Brain Injury in Active-Duty United States Special Operations Forces With Repeated Blast Exposure

United States100 participantsStarted 2025-10-14

Plain-language summary

This is a 4-year, longitudinal study of 100 active-duty Navy SEALs. The goal of the study is to determine whether repeated blast exposure affects SEAL brain health and to develop an initial diagnostic testing protocol that detects repeated blast brain injury.

Who can participate

Age range18 Years – 50 Years

SexMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Active-duty Navy SEAL Service Member
✓. Early career SEAL (0-2 years) or mid-late career SEAL (10-15 years)
✓. Age 18-50 years
✓. Males, regardless of race or ethnicity

Exclusion criteria

✕. History of moderate or severe TBI
✕. History of major neurological disorder
✕. Untreated or unstable severe psychiatric condition
✕. Current severe medical condition that requires long-term treatment
✕. Any condition that may cause undue risk to the participant or create a logistical contraindication
✕. MRI contraindication
✕. PET contraindication

What they're measuring

neuroimaging biomarkers

Timeframe: 1 year

blood biomarkers

Timeframe: 1 year

neuropsychiatric symptoms

Timeframe: 1 year

Trial details

NCT IDNCT07131475

SponsorMassachusetts General Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2029-04-30

Contact for this trial

Brian L Edlow, M.D.

617-724-6352 bedlow@mgh.harvard.edu

View on ClinicalTrials.gov More Blast Injury trials